Martin Busch

Development and validation of a renal risk score in ANCA-associated glomerulonephritis

Silke R. Brix, Mercedes Noriega, Pierre Tennstedt et al. · Kidney International · 2018 · 276 citations

Glomerular Disease, Anca-associated Glomerulonephritis, Renal Risk Score +17

Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial

Brad H. Rovin, Jonathan Barratt, Hiddo J.L. Heerspink et al. · The Lancet · 2023 · 224 citations · Full text

Disease burden and risk profile in referred patients with moderate chronic kidney disease: composition of the German Chronic Kidney Disease (GCKD) cohort

Stephanie Titze, Matthias Schmid, Anna Köttgen et al. · Nephrology Dialysis Transplantation · 2014 · 205 citations · Full text

Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial

Hiddo J.L. Heerspink, Jai Radhakrishnan, Charles E. Alpers et al. · The Lancet · 2023 · 203 citations · Full text

Glomerulonephritis, Active-controlled Clinical Trial, Renal Function +9

Effects of Early Empagliflozin Initiation on Diuresis and Kidney Function in Patients With Acute Decompensated Heart Failure (EMPAG-HF)

P. Christian Schulze, Jürgen Bogoviku, Julian Westphal et al. · Circulation · 2022 · 202 citations · Full text